Cediranib
| File:AZD2171.svg | |
| Systematic (IUPAC) name | |
|---|---|
|
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline | |
| Clinical data | |
| Routes of administration | Oral |
| Pharmacokinetic data | |
| Biological half-life | 12 to 35 hours |
| Identifiers | |
| ATC code | none |
| Chemical data | |
| Formula | C25H27FN4O3 |
| Molar mass | 450.505 g/mol[[Script error: No such module "String".]] |
| Script error: No such module "collapsible list". | |
| (verify) | |
Cediranib (tentative trade name Recentin), also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.[1][2][3]
It is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration.
Beginning in 2007, it is undergoing Phase I clinical trials for the treatment of non-small cell lung cancer, kidney cancer, and colorectal cancer in adults, as well as tumors of the central nervous system in children. Phase I trials of interactions with other drugs used in cancer treatment are also underway.
On February 27, 2008, AstraZeneca announced that the use of Recentin in non-small cell lung cancer will not progress into phase III after failing to meet its main goal.
On 8th March 2010, AstraZeneca issued a press-release stating that Recentin had failed Phase III clinical trials for use in first-line metastatic colorectal cancer when it was compared clinically with the market-leader Avastin.
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />http://www.astrazeneca.com/media/latest-press-releases/2010-new/recoentin-horizon?itemId=8748245
External links
 |
This pharmacology-related article is a stub. You can help ssf by expanding it. |
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Drugboxes which contain changes to watched fields
- 2Fix
- Tyrosine kinase inhibitors
- Indoles
- Quinazolines
- Organofluorides
- Phenol ethers
- Pyrrolidines
- Pharmacology stubs
